BEHIND RIABNI® Identical Dosing & Administration

RIABNI® HAS THE SAME DOSING SCHEDULE AS RITUXAN®1

CD20-POSITIVE B-Cell NON-HODGKIN'S LYMPHOMA (NHL)

Table name here

Schedule

RIABNI® dose

Day 1 of each cycle of chemotherapy (≤ 8 doses)

In patients with a complete or partial response, as single-agent maintenance therapy every 8 weeks for 12 doses, beginning 8 weeks after the last dose of chemotherapy

Day 1 of each cycle of chemotherapy (≤ 8 doses)

In patients with a complete or partial response, as single-agent maintenance therapy every 8 weeks for 12 doses, beginning 8 weeks after the last dose of chemotherapy

RIABNI® dose 375 mg/m2

Table name here

Schedule

RIABNI® dose

Once weekly for 4 or 8 doses RIABNI® dose 375 mg/m2

Table name here

Schedule

RIABNI® dose

Once weekly for 4 doses RIABNI® dose 375 mg/m2

Table name here

Schedule

RIABNI® dose

Following 6-8 cycles of CVP chemotherapy:

Once weekly for 4 doses at 6-month intervals (16 doses maximum)
RIABNI® dose 375 mg/m2

Table name here

Schedule

RIABNI® dose

Day 1 of each cycle of chemotherapy (≤ 8 infusions) RIABNI® dose 375 mg/m2

Chronic lymphocytic leukemia (CLL)

Table name here

Schedule

RIABNI® dose

Cycle 1: One day prior to initiation of FC chemotherapy RIABNI® dose 375 mg/m2
Cycles 2-6: Day 1 of FC chemotherapy cycles (every 28 days) RIABNI® dose Cycle 1: 375 mg/m2
Cycles 2-6: 500 mg/m2 Cycles 2-6: Day 1 of FC chemotherapy cycles (every 28 days) 500 mg/m2
  • CVP = cyclophosphamide, vincristine, prednisone; FC = fludarabine, cyclophosphamide.

Find and download additional dosing resources

RIABNI® has the same administration and infusion rates as Rituxan®1

ADMINISTRATION GUIDELINES

  • Interrupt the infusion or slow the infusion rate for infusion-related reactions
  • See Boxed WARNINGS, Dosage and Administration, Warnings and Precautions, and Adverse Reactions sections of the full Prescribing Information
FIRST INFUSION
Infusion Rate
  • Initiate infusion at a rate of 50 mg/hr
  • In the absence of infusion toxicity, increase rate by 50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hr
SUBSEQUENT STANDARD INFUSION
Infusion Rate
  • Initiate infusion at a rate of 100 mg/hr
  • In the absence of infusion toxicity, increase rate by 100 mg/hr increments at 30 minute intervals, to a maximum of 400 mg/hr
SUBSEQUENT 90-MINUTE INFUSION (For Previously Untreated Follicular NHL and DLBCL Patients)
Infusion Rate

If patients did not experience a Grade 3 or 4 infusion-related adverse event during Cycle 1, a 90-minute infusion can be administered in Cycle 2 with a glucocorticoid-containing chemotherapy regimen. If the 90-minute infusion is tolerated in Cycle 2, the same rate can be used when administering the remainder of the treatment regimen (through Cycle 6 or 8).

  • Initiate at a rate of 20% of the total dose given in the first 30 minutes and the remaining 80% of the total dose over the next 60 minutes
  • Patients who have clinically significant cardiovascular disease or who have a circulating lymphocyte count 5000/mm3 before Cycle 2 should not be administered the 90-minute infusion
RIABNI® has an established Q-CODE: Q5123

Download Nurse Dosing Guide

Learn more about
storage and
handling for RIABNI®

×
Amgen stands with our local Los Angeles community. Click here to learn what we are doing to support and contact us if the fires have impacted your access to Amgen medication.